394 related articles for article (PubMed ID: 11094035)
1. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Zannad F; Alla F; Dousset B; Perez A; Pitt B
Circulation; 2000 Nov; 102(22):2700-6. PubMed ID: 11094035
[TBL] [Abstract][Full Text] [Related]
2. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Zannad F; Dousset B; Alla F
Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
[TBL] [Abstract][Full Text] [Related]
3. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Ferreira JP; Duarte K; Montalescot G; Pitt B; de Sa EL; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Rossignol P; Vincent J; Zannad F
Clin Res Cardiol; 2018 Jan; 107(1):49-59. PubMed ID: 28852839
[TBL] [Abstract][Full Text] [Related]
4. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
MacFadyen RJ; Barr CS; Struthers AD
Cardiovasc Res; 1997 Jul; 35(1):30-4. PubMed ID: 9302344
[TBL] [Abstract][Full Text] [Related]
6. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
Glick HA; Orzol SM; Tooley JF; Remme WJ; Sasayama S; Pitt B
Cardiovasc Drugs Ther; 2002 Jan; 16(1):53-9. PubMed ID: 12085979
[TBL] [Abstract][Full Text] [Related]
9. Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure.
Kunin M; Carmon V; Beckerman P; Dinour D
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31141909
[TBL] [Abstract][Full Text] [Related]
10. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
Macdonald JE; Kennedy N; Struthers AD
Heart; 2004 Jul; 90(7):765-70. PubMed ID: 15201246
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Horie H; Sugimoto Y; Kinoshita M
J Am Coll Cardiol; 2000 Sep; 36(3):838-44. PubMed ID: 10987608
[TBL] [Abstract][Full Text] [Related]
12. [Study of the month. The RALES study (randomized aldactone evaluation study].
Kulbertus H
Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
15. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Matsui T; Kinoshita M
J Am Coll Cardiol; 2001 Apr; 37(5):1228-33. PubMed ID: 11300427
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
[TBL] [Abstract][Full Text] [Related]
17. Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Cavallari LH; Momary KM; Groo VL; Viana MA; Camp JR; Stamos TD
Pharmacotherapy; 2007 Jun; 27(6):801-12. PubMed ID: 17542763
[TBL] [Abstract][Full Text] [Related]
18. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
Vardeny O; Wu DH; Desai A; Rossignol P; Zannad F; Pitt B; Solomon SD;
J Am Coll Cardiol; 2012 Nov; 60(20):2082-9. PubMed ID: 23083787
[TBL] [Abstract][Full Text] [Related]
19. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
Stienen S; Rossignol P; Barros A; Girerd N; Pitt B; Zannad F; Ferreira JP
Clin Res Cardiol; 2020 Feb; 109(2):194-204. PubMed ID: 31250134
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
Pitt D
Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
